Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CADL Candel Therapeutics, Inc.

Closed Memorial Day 05-22 16:00:00 EDT

7.99

+0.06

+0.76%

盘后8.00

+0.01+0.13%

19:36 EDT

High8.34	Low7.90	Vol1.59M
Open7.99	D1 Closing7.93	Amplitude5.55%
Mkt Cap585.22M	Tradable Cap363.37M	Total Shares73.24M
T/O12.90M	T/O Rate3.49%	Tradable Shares45.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CADL","market":"US","secType":"STK","nameCN":"Candel Therapeutics, Inc.","latestPrice":7.99,"timestamp":1779480000000,"preClose":7.93,"halted":0,"volume":1588113,"hourTrading":{"tag":"盘后","latestPrice":8,"preClose":7.99,"latestTime":"19:36 EDT","volume":13951,"amount":111522.2543,"timestamp":1779492964687,"change":0.01,"changeRate":0.001252,"amplitude":0.005006},"delay":0,"changeRate":0.007566204287515826,"floatShares":45478500,"shares":73244500,"eps":-0.973062,"marketStatus":"Closed Memorial Day","change":0.06,"latestTime":"05-22 16:00:00 EDT","open":7.99,"high":8.34,"low":7.9,"amount":12903718.278357001,"amplitude":0.055485,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.973062,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"listingDate":1627358400000,"exchange":"NASDAQ","adjPreClose":7.93,"preHourTrading":{"tag":"盘前","latestPrice":8.06,"preClose":7.93,"latestTime":"09:15 EDT","volume":3446,"amount":27577.590218,"timestamp":1779455744866,"change":0.13,"changeRate":0.016393,"amplitude":0.037831},"postHourTrading":{"tag":"盘后","latestPrice":8,"preClose":7.99,"latestTime":"19:36 EDT","volume":13951,"amount":111522.2543,"timestamp":1779492964687,"change":0.01,"changeRate":0.001252,"amplitude":0.005006},"volumeRatio":0.6130206070734583,"impliedVol":0.4724,"impliedVolPercentile":0.1753},"requestUrl":"/m/hq/s/CADL/wiki","defaultTab":"wiki","newsList":[{"id":"2636300636","title":"Candel Therapeutics price target raised to $9 from $7 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2636300636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636300636?lang=en_us&edition=fundamental","pubTime":"2026-05-19 03:30","pubTimestamp":1779132609,"startTime":"0","endTime":"0","summary":"BofA analyst Alec Stranahan raised the firm’s price target on Candel Therapeutics (CADL) to $9 from $7 and keeps a Neutral rating on the shares. Ca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-price-target-raised-to-9-from-7-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-price-target-raised-to-9-from-7-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635806055","title":"Candel Therapeutics Highlights Phase 3 Prostate Cancer Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2635806055","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635806055?lang=en_us&edition=fundamental","pubTime":"2026-05-16 06:08","pubTimestamp":1778882908,"startTime":"0","endTime":"0","summary":"Candel Therapeutics ( ($CADL) ) has provided an announcement. On May 15, 2026, Candel Therapeutics held a live investor webcast in conjunction with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-highlights-phase-3-prostate-cancer-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-highlights-phase-3-prostate-cancer-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","CADL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635968037","title":"Candel says CAN-2409 cuts prostate cancer recurrence risk 39% in Phase 3 follow-up","url":"https://stock-news.laohu8.com/highlight/detail?id=2635968037","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635968037?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:07","pubTimestamp":1778875637,"startTime":"0","endTime":"0","summary":"Candel Therapeutics disclosed extended follow-up results from its pivotal Phase 3 trial of CAN-2409 in intermediate- to high-risk localized prostate cancer, presented at AUA 2026.Prolonged follow-up continued to show fewer prostate cancer recurrences versus placebo when CAN-2409 was added to standard radiotherapy.Secondary readouts also favored CAN-2409, pointing to longer periods before disease progression and reduced spread, though most measures remained exploratory at this stage.Candel plans to submit a Biologics License Application to US FDA in Q4 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL2n7VJ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4539","SG9999014013.SGD","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014005.SGD","SG9999014039.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","NDAQ","BK4588","BK4139","LU2095319765.USD","IE00BN0W2W23.USD","CADL","IE00BN0W2T93.GBP","BK4585","BK4112","IE00B64PRP62.GBP","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037502","title":"Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients From Phase 3 Trial of Aglatimagene Besadenovec (Can-2409) in Localized Prostate Cancer Under Prolonged Follow-up at Aua 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037502","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037502?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:05","pubTimestamp":1778875500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUABQGYQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635908037","title":"Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2635908037","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635908037?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:05","pubTimestamp":1778875500,"startTime":"0","endTime":"0","summary":"Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prosta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/15/3296125/0/en/Candel-Therapeutics-Reports-Extended-Clinical-Benefit-Over-Multiple-Clinical-Endpoints-in-Patients-from-Phase-3-Trial-of-Aglatimagene-Besadenovec-CAN-2409-in-Localized-Prostate-Can.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0053671581.USD","BK4166","LU0054578231.USD","LU1861217088.USD","BK4585","BK4523","LU1861220207.SGD","CADL","BK4170","BK4595","BK4539","BK4139","BK4600","BK4109","LU1668664300.SGD","LU2360107671.USD","BK4526","BK4099","LU1791807156.HKD","LU0106831901.USD","BK4161","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089891","title":"Canaccord Genuity Reaffirms Their Buy Rating on Candel Therapeutics (CADL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089891","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089891?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:11","pubTimestamp":1778843515,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst John Newman maintained a Buy rating on Candel Therapeutics today and set a price target of $25.00. Newman covers the Heal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-candel-therapeutics-cadl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-candel-therapeutics-cadl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635085553","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Pyxis Oncology (PYXS) and Candel Therapeutics (CADL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635085553","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635085553?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:30","pubTimestamp":1778841020,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Humana (HUM), Pyxis Oncology (PYXS) and Candel The...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-humana-hum-pyxis-oncology-pyxs-and-candel-therapeutics-cadl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-humana-hum-pyxis-oncology-pyxs-and-candel-therapeutics-cadl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0029874061.USD","BK4539","LU1093756168.USD","LU1093756325.SGD","SG9999014005.SGD","LU0320765489.SGD","XLV","LABU","LU0256863811.USD","LU0417517546.SGD","LU0211331839.USD","LU0348723411.USD","HUM","LU0208291251.USD","BK4581","BK4566","SG9999014013.SGD","BK4588","BK4137","LU1983260115.SGD","LU0128526141.USD","HCSG","LU0390134368.USD","SG9999014021.USD","LU0266013472.USD","XBI","BK4154","BK4139","LU0238689110.USD","LU0070302665.USD","BK4533","PYXS","LU0170899867.USD","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635289267","title":"Candel Therapeutics publishes corporate presentation on viral immunotherapies for solid tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2635289267","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635289267?lang=en_us&edition=fundamental","pubTime":"2026-05-15 03:52","pubTimestamp":1778788369,"startTime":"0","endTime":"0","summary":"Candel Therapeutics investor presentation highlighted positive phase 3 data for lead candidate aglatimagene besadenovec  in localized, intermediate- to high-risk prostate cancer, with trial meeting primary endpoint of disease-free survival.Program also cited positive overall survival signals from randomized phase 2a studies in borderline resectable pancreatic cancer, with additional phase 2a overall survival data in therapy-resistant non-small cell lung cancer.Regulatory status includes FDA RMAT designation in prostate cancer, Fast Track designations in prostate, NSCLC, pancreatic cancer, with Orphan Drug designation in pancreatic cancer.Balance sheet snapshot showed cash and cash equivalents of $194.8 million as of March 31, 2026, with expected runway into Q1 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL1B8JXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4139","CADL","BK4539","TRIN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635749491","title":"Candel Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635749491","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635749491?lang=en_us&edition=fundamental","pubTime":"2026-05-14 23:36","pubTimestamp":1778773014,"startTime":"0","endTime":"0","summary":"Candel Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryCandel Therapeutics Inc CADL.OQ reported a quarterly adjusted loss of 14 cents per share for the quarter ended ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R1VK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635220712","title":"Candel Therapeutics reports Q1 loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2635220712","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635220712?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:15","pubTimestamp":1778760959,"startTime":"0","endTime":"0","summary":"Candel Therapeutics reports Q1 lossOverviewU.S. cancer immunotherapy developer posted Q1 net loss, reversing prior-year net profitCompany ended Q1 with $194.8 mln cash, expects runway into Q1 2028Outl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL1N41R0LD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635971245","title":"Candel Therapeutics Q1 EPS $(0.14) Beats $(0.34) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635971245","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635971245?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:12","pubTimestamp":1778760738,"startTime":"0","endTime":"0","summary":"Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.34) by 58.82 percent. This is a 207.69 percent decrease over earnings of $0.13 per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52556803/candel-therapeutics-q1-eps-0-14-beats-0-34-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635126217","title":"BRIEF-Candel Therapeutics Q1 Net Income USD -8.861 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635126217","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635126217?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:05","pubTimestamp":1778760345,"startTime":"0","endTime":"0","summary":"BRIEF-Candel Therapeutics Q1 Net Income USD -8.861 Million\n\n\nMay 14 (Reuters) - Candel Therapeutics Q1 operating expenses USD 16.284 million.\n\nQ1 income from operations USD -16.284 million vs. IBES estimate USD -16.8 million\nQ1 basic EPS USD -0.14","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLXB499C6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635771257","title":"Candel Therapeutics Q1 Operating Expenses USD 16.284 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635771257","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635771257?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:05","pubTimestamp":1778760300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLXB499C6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635712620","title":"Press Release: Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635712620","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635712620?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:05","pubTimestamp":1778760300,"startTime":"0","endTime":"0","summary":"-- Company plans to submit a Biologics License Application  for. intermediate- to high-risk prostate cancer in Q4 2026. -- Announced purpose-built commercial partnership with EVERSANA to. support potential U.S. launch of aglatimagene in localized prostate. Dr. Tak continued, \"On the commercial readiness front, we are encouraged by our progress in building a differentiated, partnership-driven model that leverages the expertise of world-class organizations EVERSANA and IDEA Pharma. We believe this approach can enhance speed, flexibility, and scalability, positioning Candel for a successful and timely commercial launch of aglatimagene, if approved, for patients with localized pros","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0170899867.USD","CMC","IE00BZ1G4Q59.USD","LU1363072403.SGD","BK4585","IE00BFXG1179.USD","LU2237443978.SGD","LU0882574139.USD","LU2237443895.HKD","LU2237443382.USD","BK4539","LU2237443465.HKD","R","IE00B1BXHZ80.USD","LU2237443549.SGD","IE00BHPRN162.USD","BK4139","BK4006","CADL","LU2746668974.SGD","BK4232","LU0267386448.USD","BK4588","LU2746668461.USD","LABU","IE00BKVL7J92.USD","BK4022","LU2237443622.USD","LU0971096721.USD","LU0149725797.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635784937","title":"Candel Therapeutics CEO presents at Stifel Virtual Targeted Oncology Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2635784937","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635784937?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:07","pubTimestamp":1778674063,"startTime":"0","endTime":"0","summary":"Candel Therapeutics scheduled to present at Stifel 2026 Virtual Targeted Oncology Forum on May 20, 2026 at 10:00 a.m. ET.Presentation slated for 2026 Jefferies Global Healthcare Conference in New York on June 3, 2026 at 5:30 p.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL4F2Q7q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4112","BK4585","NDAQ","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","CADL","LU2210150020.SGD","SG9999014021.USD","SF","IE00BGHQF748.EUR","BK4139","SG9999014039.USD","BK4588","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BK4127","BK4539","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635782776","title":"Candel Therapeutics to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2635782776","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635782776?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:05","pubTimestamp":1778673900,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., May  13, 2026  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunot","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293960/0/en/Candel-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633325468","title":"Candel Therapeutics Inc  expected to post a loss of 32 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633325468","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633325468?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:30","pubTimestamp":1778254228,"startTime":"0","endTime":"0","summary":"Candel Therapeutics Inc  expected to post a loss of32cents a share - Earnings Preview Candel Therapeutics Inc CADL.OQ CADL.O is expected to  show no change in quarterly revenue when it reports  result","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1UX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632765958","title":"Candel Therapeutics updates Phase 3 CAN-2409 data in localized prostate cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2632765958","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632765958?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:07","pubTimestamp":1777896431,"startTime":"0","endTime":"0","summary":"Candel Therapeutics scheduled investor webcast for May 15, 2026, to discuss extended follow-up from its phase 3 trial of aglatimagene besadenovec  in intermediate- to high-risk localized prostate cancer.Results will be presented in a future oral plenary session at American Urological Association 2026 Annual Meeting, with call set to follow that presentation.Update centers on longer-term patient outcomes from the late-stage study, a key readout for assessing whether CAN-2409 can support a regulatory path in localized prostate cancer.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLbMtxGt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2210150020.SGD","IE00BKPKM429.USD","BK4539","BK4139","LU2210149790.SGD","NDAQ","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","SG9999014005.SGD","BK4588","BK4585","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU0314104364.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","CADL","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632642091","title":"Candel Therapeutics grants new-hire inducement options for 29,400 shares at $6.18 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2632642091","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632642091?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:07","pubTimestamp":1777666026,"startTime":"0","endTime":"0","summary":"Candel Therapeutics granted inducement stock options covering 29,400 common shares to two new employees on April 30, 2026.Exercise price set at USD 6.18 per share.Vesting starts with 25% on first anniversary of employee start date.Remaining 75% vests in 36 equal monthly installments, subject to continued service.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL6dSDDp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","SG9999014039.USD","BK4588","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4539","IE00BN0W2T93.GBP","SG9999014021.USD","SG9999014005.SGD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","BK4112","CADL","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632642078","title":"Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632642078","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632642078?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:05","pubTimestamp":1777665900,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., May  01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3286208/0/en/Candel-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CADL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.candeltx.com","stockEarnings":[{"period":"1week","weight":-0.0889},{"period":"1month","weight":0.0886},{"period":"3month","weight":0.5651},{"period":"6month","weight":0.756},{"period":"1year","weight":0.4742},{"period":"ytd","weight":0.4142}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.056687},{"month":2,"riseRate":0.4,"avgChangeRate":0.052018},{"month":3,"riseRate":0.2,"avgChangeRate":-0.120448},{"month":4,"riseRate":0.4,"avgChangeRate":0.650234},{"month":5,"riseRate":1,"avgChangeRate":0.177777},{"month":6,"riseRate":0,"avgChangeRate":-0.170269},{"month":7,"riseRate":0.25,"avgChangeRate":0.011025},{"month":8,"riseRate":0.8,"avgChangeRate":0.068985},{"month":9,"riseRate":0.4,"avgChangeRate":-0.01705},{"month":10,"riseRate":0.4,"avgChangeRate":-0.110246},{"month":11,"riseRate":0,"avgChangeRate":-0.079739},{"month":12,"riseRate":0.8,"avgChangeRate":0.288433}],"exchange":"NASDAQ","name":"Candel Therapeutics, Inc.","nameEN":"Candel Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Candel Therapeutics, Inc.,CADL,Candel Therapeutics, Inc.股票,Candel Therapeutics, Inc.股票老虎,Candel Therapeutics, Inc.股票老虎国际,Candel Therapeutics, Inc.行情,Candel Therapeutics, Inc.股票行情,Candel Therapeutics, Inc.股价,Candel Therapeutics, Inc.股市,Candel Therapeutics, Inc.股票价格,Candel Therapeutics, Inc.股票交易,Candel Therapeutics, Inc.股票购买,Candel Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction